GlassScriptPhysician profile
Katayun Adhami
NPI 1679867766
$559.94
in general payments reported to CMS, 2019-2025
14 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.33 · 2023: $72.16 · 2024: $161 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $127.57 | 2023-2025 | Sotyktu |
| Abbvie INC. | $87.46 | 2024-2025 | |
| Revance Therapeutics, INC. | $63.66 | 2024 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $57.76 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $31.94 | 2025 | |
| Incyte Corporation | $28.22 | 2025 | Opzelura |
| Pfizer INC. | $28.09 | 2025 | |
| Genzyme Corporation | $24.33 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.45 | 2023 | Ilumya |
| Ucb, INC. | $20.26 | 2025 | Bimzelx |
| Mimedx Group, INC. | $20.18 | 2024 | |
| Lilly USA, LLC | $17.56 | 2024 | Zepbound, Taltz |
| Arcutis Biotherapeutics, INC. | $16.48 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $14.98 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katayun Adhami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.